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Abstract
Use of complementary and alternative medicine by males with Duchenne or Becker muscular 
dystrophy was examined using interview reports from caregivers enrolled in the population-based 
Muscular Dystrophy Surveillance, Tracking, and Research Network. Of the 200 caregivers 
interviewed, 160 (80%) reported “ever” using complementary and alternative medicine for their 
affected children. Mind-body medicine (61.5%) was most frequently used, followed by 
biologically based practices (48.0%), manipulative and body-based practices (29.0%), and whole 
medical systems (8.5%). Caregivers reporting use of whole medical systems had higher education 
and income levels compared with nonusers; affected males had shorter disease duration. 
Caregivers reporting use of mind-body medicine, excluding aquatherapy, had higher education 
level compared with nonusers. Overall, complementary and alternative medicine use was high; 
disease duration, education, and income levels influenced use. These findings have implications 
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for developing clinical care protocols and monitoring possible interactions between 
complementary and alternative medicine and conventional medical therapies.
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Complementary and alternative medicine is a diverse group of medical and healthcare 
practices that are not generally considered conventional therapy.1 Complementary medicine 
is used in conjunction with conventional therapy, whereas alternative medicine is used in 
place of conventional medicine.1 Use of complementary and alternative medicine to manage 
chronic illness is common worldwide, with estimates ranging from 6% to 65% in adults.2 In 
particular, a 2007 report revealed that 38.3% adults in the United States used complementary 
and alternative medicine.3
Use of complementary and alternative medicine has also been reported in pediatric 
populations,4–9 especially among children with chronic disease or disability.4,10,11 Higher 
rates of use are reported in children with chronic conditions not amendable to surgical 
treatment (eg, cerebral palsy)12 compared with those that can be surgically repaired (eg, cleft 
lip and/or palate).10 Two Canadian studies that examined use of complementary and 
alternative medicine in pediatric patients with neurologic disorders reported rates of 30% in 
patients with neuromuscular disease in general13 and 20% in patients with Duchenne 
muscular dystrophy.14
A variety of complementary and alternative therapies have been reported among pediatric 
populations, including chiropractic manipulation, herbal therapy, homeopathy, prayer, 
massage, special diets, megavitamins, acupuncture, and aquatherapy.4,7,10,12–14 Factors 
noted to influence use included child age6,7,12 and disease state,12 parent/caregiver age,6 
race,7 and use of complementary and alternative medicine,6–10,12 maternal education level,12 
healthcare provider recommendation,10 and geographical region of residence8,9; however, 
these findings have not been consistently replicated. A common limitation of many studies is 
the use of small clinic-based samples.7,13,14 In addition, some studies have not focused on 
complementary and alternative medicine use in children with specific chronic conditions, but 
rather studied use among children receiving services in special needs clinics.10,14
With the increase in complementary and alternative medicine use among children with 
chronic disease or disability, improved understanding of types and patterns of such use for 
specific conditions is needed. This is particularly important as clinical trials of new potential 
therapies are being designed. To address this gap, use of complementary and alternative 
medicine and factors influencing such use were examined in a population-based cohort of 
males with childhood-onset Duchenne or Becker muscular dystrophy identified by the 
Muscular Dystrophy Surveillance, Tracking, and Research Network.
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Methods
The Muscular Dystrophy Surveillance, Tracking, and Research Network is a multisite 
project established by the Centers for Disease Control and Prevention in 2002. Initially, it 
was composed of 4 sites: Arizona, Colorado, Iowa, and New York. More recently, activities 
were expanded to Georgia in 2005 and Hawaii in 2008. The methods for surveillance 
activities have been described elsewhere.15 Briefly, each site conducts population-based 
surveillance for Duchenne or Becker muscular dystrophy statewide, with the exception of 
New York, which conducts surveillance in 12 western counties. An individual with 
Duchenne or Becker muscular dystrophy was eligible for inclusion if born on or after 
January 1, 1982, and was a resident in any Muscular Dystrophy Surveillance, Tracking, and 
Research Network site. For each potential case identified, information abstracted was used 
to assign 1 of 6 case definitions (definite, probable, possible, asymptomatic, affected female, 
or not Duchenne or Becker muscular dystrophy).16 The present analysis was restricted to 
males with a definite or probable clinical diagnosis of Duchenne or Becker muscular 
dystrophy as evidenced by an elevated creatine kinase level, and either documentation of a 
dystrophin mutation, a muscle biopsy that showed abnormal dystrophin by immunostaining 
or Western blot, or a documented family history of an X-linked muscular dystrophy.16
As an extension of the surveillance activities, baseline interviews were conducted with 
primary caregivers to examine socioeconomic and acculturation factors, family 
characteristics, geography, social support, clinical outcomes, and use of complementary and 
alternative medicine, medical services, and assistive technology. A telephone interview 
instrument was developed with closed and open-ended questions. Items related to use of 
complementary and alternative medicine were developed based on previous research on 
children with special healthcare needs.9,10
Survey Sample and Baseline Telephone Interview
The population for the baseline telephone interviews was composed of the primary 
caregivers of 464 males (living or deceased) identified during the first 2 surveillance years 
(April 2004–August 2006) from Arizona, Colorado, Georgia, Iowa, and western New York. 
Individuals from Hawaii were not included because surveillance had not commenced by 
2006. Of the 464 males, all 43 from Georgia were excluded as surveillance was not complete 
for the entire catchment area. Also excluded were 1 male who had moved out of the United 
States and 1 male who was later determined not to have Duchenne or Becker muscular 
dystrophy, resulting in a sample of 419 males. For these 419 males, there were 372 
independent caregivers. Eligible primary caregivers (in priority order) were birth mother, 
birth father, and legal guardian; only 1 caregiver was selected per family.
From April 2007 through May 2008, caregivers were contacted to participate in the 
interview. Recruitment was initiated directly with caregivers by mail (Iowa and New York), 
telephone (Colorado), or indirectly by mail through the primary healthcare provider 
(Arizona). Following the initial contact, each caregiver was sent a study packet with an 
introductory letter, project brochure, information on frequently asked questions and rights of 
research subjects, a residence history worksheet, and $20 compensation for time and effort 
required to complete the interview. A systematic follow-up protocol by telephone and mail 
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was used to obtain consent to conduct the interviews. The interviews were administered in 
English or Spanish language by trained interviewers and typically took between 45 and 60 
minutes to complete, depending on the age and number of affected males in the family. In 
families with more than 1 affected male, a short additional module was completed to provide 
data on younger affected sibling(s). Regarding use of complementary and alternative 
medicine, caregivers were asked if an affected male had ever used any medicines read from a 
prespecified list. To obtain a more complete picture of use, caregivers had the option to 
report any other complementary and alternative therapies used. If caregivers indicated use of 
special diet, they were asked to indicate the type of diet. In addition, caregivers were asked if 
each complementary and alternative therapy used was recommended by a healthcare 
provider.
For every completed interview, the respective interviewer and interview supervisor each 
conducted a manual review of item responses recorded to identify entry errors and the need 
for callbacks with a caregiver. Local institutional review board approval to conduct interview 
data collection with primary caregivers was obtained at each site.
Data Analysis
Deidentified interview data from each participating site were pooled at the Data 
Coordination Center (interview data, release date April 2009) and used for analysis. 
Surveillance data were used to provide sociodemographic information on nonparticipants to 
examine possible participation bias. Interview data were used to evaluate factors that 
influence use of complementary and alternative medicine. Because use of complementary 
and alternative medicine is likely to be correlated in families with multiple affected males, 
the family unit was used as the unit of analysis. Caregiver characteristics examined were age 
at interview (25–39, 40–49, 50–64 years), race/ethnicity as reported by the caregiver (white 
non-Hispanic, Hispanic, other), education level (≤high school, some college or vocational 
training, college graduate), and current marital status if the caregiver was the biological 
parent (single, married). Affected male characteristics were person-years with disease and 
disease phenotype. Person-years were calculated as the difference between age at interview 
and age at diagnosis. If the index child was deceased at the time of the interview, the age at 
death was substituted for the age at interview. Disease phenotype was based on age of onset 
of signs and symptoms. Affected males with signs and symptoms before their sixth birthday 
were classified as early onset, which was used as a proxy for Duchenne muscular dystrophy. 
If signs and symptoms started after the sixth birthday, then age of onset was classified as late 
and used as a proxy for Becker muscular dystrophy. Additional variables examined were site 
(Arizona, Colorado, Iowa, western New York) and family household income (<$30 000, $30 
000–$50 000, >$50 000).
Use of complementary and alternative medicine was the outcome variable, and it was 
examined based on domains defined by the National Center for Complementary and 
Alternative Medicine.1 These domains were biologically based practices (eg, dietary 
supplements, herbal products, special diets, or vitamins), manipulative and body-based 
practices (eg, firecupping, gwa sha, chiropractic or osteopathic manipulation, massage, 
myofascial release, electro- and laser therapy), mind-body medicine (eg, aquatherapy, 
Nabukera et al. Page 4
J Child Neurol. Author manuscript; available in PMC 2018 April 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
companion animals, hippotherapy, hypnosis, meditation, music therapy, prayer, or yoga), 
and whole medical systems (eg, acupuncture, homeopathy, or Qi gong).
Bivariable analyses were conducted to examine associations between the affected male’s 
person-years of disease, caregiver characteristics (age, race/ethnicity, marital status, and 
education level), site, family income, and use of specific complementary and alternative 
medicine domains. For each domain examined, the comparison group included caregivers 
who reported no use of complementary and alternative medicine. Since special diets (eg, 
low-fat diets) and aquatherapy are commonly recommended practices in the management of 
Duchenne or Becker muscular dystrophy,17 analyses for the biologically based 
complementary and alternative medicine domain included all families who reported use of 
special diet and excluded families who reported use of special diet only (n = 11). Similarly, 
analyses for mind-body medicine included all families who reported use of aqua-therapy and 
excluded families who reported use of aquatherapy only (n = 17). t tests and chi-squares 
were used to test for significant differences in means and proportions (P < .05). Observations 
with unknown or missing responses were excluded from analyses.
Results
Of the 372 eligible caregivers, 200 (53.8%) completed interviews, 2 (0.5%) consented but 
were unable to complete interviews by the close of data collection, 84 (22.6%) refused, and 
86 (23.1%) were not located. Participation rates for each individual site were 42.6% in 
Arizona, 50.0% in Colorado, 71.4% in Iowa, and 62.2% in western New York. Overall, 
caregivers were more likely to participate if both parents were identified as caregivers; 
mothers were most often the primary respondent 175 (87.5%). Based on surveillance data, 
mothers who participated were more likely than nonparticipants to be older, white non-
Hispanic, and to have at least a high school education (Table 1). For other participants (eg, 
fathers), corresponding data on nonparticipants were not available for comparison.
Among caregiver participants, the median age at interview was 44 years, and one-half 
reported a family income greater than $50 000. Among the 200 affected males, 162 (81.0%) 
had early onset of signs and symptoms, 37 (18.5%) had late onset, and 1 affected male had 
undetermined age at onset. The median ages at interview and at diagnosis of Duchenne or 
Becker muscular dystrophy for the oldest affected males were 16 and 4.5 years, respectively, 
and mean person-years of disease was 11 years 2 months ± 5 years 1 month (data not 
shown).
Of the 200 caregiver participants, 160 (80%) reported “ever” using complementary and 
alternative medicine for their affected children. There was no significant difference in 
reported use between caregivers of males with early onset of signs and symptoms and those 
of males with late onset (82.1% vs 70.3%; P value = .11); therefore, further analyses 
combined both groups. The number of complementary and alternative therapies reported 
ranged from 1 to 9 per family. Of the caregivers who reported use of complementary and 
alternative medicine, 55 (34%) reported use of 1, 42 (26%) reported 2, 26 (16%) reported 3, 
15 (9%) reported 4, and 22 (14%) reported 5 or more (data not shown). Aquatherapy, prayer, 
and special diets (commonly low fat or low calorie) were most often reported (Table 2). 
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Reports of “other” complementary and alternative medicine included such therapies as 
creatine, coenzyme Q10, fire cupping, qwa sha, electro- and laser therapy, and Qi gong (data 
not shown). Aquatherapy and special diets were most often reported to have been 
recommended by healthcare providers. Excluding families that reported use of aquatherapy 
only, diet only, or both (Figure 1), there was only a slight decline in the overall use of 
complementary and alternative medicine.
Based on the complementary and alternative medicine domains, use of mind-body medicine 
was most commonly reported (n = 123; 61.5%), followed by biologically based practices (n 
= 96; 48.0%). Use of manipulative and body-based practices was reported by 58 (29.0%) 
caregivers, and 17 (8.5%) reported use of whole medical systems (data not shown). 
Caregivers frequently reported use of complementary and alternative medicine across 
multiple domains as shown in Table 3.
In bivariable analyses (Table 4), significant associations were found between use of whole 
medical systems (acupuncture, homeopathy, and Qi gong) and person-years of disease, 
caregiver education level, and family income. Compared with nonusers, males who used 
complementary and alternative medicine in the whole medical system domain had 
significantly shorter duration of disease (t-test P value = 0.02), and their caregivers had a 
college education or higher and family income >$50 000 (exact P value < .05 as 
appropriate). No significant associations were observed for biologically based practices 
(with or without special diet) and manipulative and body-based practices. For mind-body 
medicine, when users of aquatherapy only were excluded, a significant association was 
observed with caregiver education level. Compared with nonusers, caregivers of males who 
used mind-body practices had a college education or higher (chi-square P value < .05).
Discussion
The proportion of reported complementary and alternative medicine use observed in this 
study was higher than has been reported for the general pediatric population,5,7,9 and in 
children with neuromuscular disorders in general,13 and muscular dystrophy in particular.
13,14
 Similarly, the proportion of use in this population was higher than what has been 
reported for adults with neurologic disorders18 or functional disabilities.19 These findings 
persisted after exclusion of complementary and alternative therapies considered part of 
conventional care for Duchenne or Becker muscular dystrophy (aquatherapy and special 
diet). Several factors, such as duration of use (lifetime use7,12,13 vs a more restricted time 
period of 6 or 12 months7,9,10,14), differences in study populations sampled,13,14 society-
wide changes in knowledge, popularity and availability of complementary and alternative 
medicine,20 and differences in classification of complementary and alternative therapies, 
might explain the discrepant findings. Similar to previously published reports,12,13 families 
enrolled in the Muscular Dystrophy Surveillance, Tracking, and Research Network tended to 
use more than 1 complementary and alternative therapy.
As has been reported in other studies of children with special healthcare needs, aquatherapy, 
special diet, and prayer were commonly reported.10,12,21,22 Aquatherapy, a specialized form 
of physical therapy performed in water, is recommended as a complement to traditional 
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physical therapy; therefore, it might well be considered a conventional form of treatment and 
not a complementary and alternative therapy. Indeed, use of aqua-therapy has been 
recommended as part of the clinical care considerations for Duchenne or Becker muscular 
dystrophy.17 Likewise, nutritional guidance (diet, vitamins, and nutrients) is a key 
component of the clinical care considerations.17 This is supported by the fact that 
aquatherapy and special diet were most likely to be recommended by healthcare providers.
Use of prayer as a coping mechanism has been reported by families with children who are 
chronically ill.22–25 Anecdotal information suggests that prayer is used by individuals with 
Duchenne or Becker muscular dystrophy to cope with their illness,26 which may explain the 
high proportion of prayer use in this population. That said, this study was unable to 
distinguish between families who reported use of prayer as a healing mechanism as opposed 
to regular prayer.
Several factors have been reported to influence use of complementary and alternative 
medicine in pediatric populations. Similar to previous reports,12,27,28 this study did find that 
caregiver education was associated with use of certain complementary and alternative 
therapies, and that use was higher in families where the caregiver had a college education.
These findings need to be considered with respect to several limitations. Because the 
interview participation rate of 53.8% was modest, there is potential for participation bias in 
this population as a significantly higher proportion of participants were older, non-Hispanic 
whites and had relatively higher education levels compared with nonparticipants. Another 
limitation was that data collected were self-reports and because complementary and 
alternative medicine use was not limited to a specific time period, it was potentially difficult 
for caregivers to recall all possible therapies used. Also, caregivers were only asked about 
physician recommendation if they reported using a specific complementary and alternative 
therapy. As a result, such recommendations could only be evaluated if the caregiver 
endorsed use and not if the therapy was recommended but not used. Lastly, missing values 
for some variables reduced the effective sample size for analysis, which may have resulted in 
the inability to detect any associations in factors that have been previously reported. Despite 
these limitations, this study is one of the few studies using a population based sample of 
males with Duchenne or Becker muscular dystrophy and their families; thus, these findings 
may be indicative of the prevalence of complementary and alternative medicine use in this 
population.
Conclusion
Findings from this study suggest a high proportion of complementary and alternative 
medicine use by males with Duchenne or Becker muscular dystrophy. Healthcare providers 
and policy makers need to be aware of the extent of such use in this population, as there may 
be implications for development of disease-specific clinical care protocols and monitoring of 
possible interactions between complementary and alternative medicine and conventional 
treatments. Further research is needed to elucidate the advantages and disadvantages of 
specific complementary and alternative therapies in alleviating symptoms, as well as any 
potential side effects of these medicines.
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Figure 1. 
Reported use of CAM by males with Duchenne or Becker muscular dystrophy.
CAM, complementary and alternative medicine.
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Table 1
Distribution of Selected Population Sociodemographic Characteristics by Participation Statusa
Affected Male and Caregiver Characteristic
Participants (N = 200)
N (%)
Nonparticipants (N = 172)
N (%) P value
MD STARnet site <.05
 Arizona 52 (26.0) 70 (40.7)
 Colorado 47 (23.5) 51 (29.7)
 Iowa 50 (25.0) 20 (11.6)
 New York 51 (25.5) 31 (18.0)
Multiple affected males .52
 Yes 30 (15.0) 30 (17.4)
 No 170 (85.0) 142 (82.6)
Caregiver relationship .65
 Mother 175 (87.5) 149 (86.6)
 Father 12 (6.0) 14 (8.1)
 Other 13 (6.5) 9 (5.2)
Language used at home .05
 English 187 (93.5) 151 (87.8)
 Spanish 8 (4.0) 18 (10.5)
 Other 5 (2.5) 3 (1.7)
Maternal year of birthb .03
 ≤1960 48 (31.2) 31 (23.3)
 1961–1965 47 (30.5) 32 (24.1)
 1966–1970 37 (24.0) 33 (24.8)
 ≥1971 22 (14.3) 37 (27.8)
Maternal race/ethnicity <.05
 White non-Hispanic 128 (64.0) 73 (42.4)
 Black non-Hispanic 5 (2.5) 4 (2.3)
 Hispanic 30 (15.0) 43 (25.0)
 Other 4 (2.0) 8 (4.7)
 Unknown 33 (16.5) 44 (25.6)
Maternal education levelb <.05
 Less than high school 17 (10.8) 28 (25.2)
 High school 56 (35.7) 49 (44.1)
 Some college 38 (24.2) 23 (20.7)
 College 40 (25.5) 7 (6.3)
 Unknown 6 (3.8) 4 (3.6)
Maternal vital status .08
 Living 192 (96.0) 171 (99.4)
 Deceased 5 (2.5) 0 (0.0)
 Unknown 3 (1.5) 1 (0.6)
Oldest affected male year of birth .61
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Affected Male and Caregiver Characteristic
Participants (N = 200)
N (%)
Nonparticipants (N = 172)
N (%) P value
 1982–1985 39 (19.5) 24 (14.0)
 1986–1990 58 (29.0) 58 (33.7)
 1991–1995 58 (29.0) 51 (29.7)
 1996–2000 38 (19.0) 31 (18.0)
 2001–2005 7 (3.5) 8 (4.7)
Oldest affected male vital status .12
 Living 173 (86.5) 135 (78.5)
 Deceased 26 (13.0) 36 (20.9)
 Unknown 1 (0.5) 1 (0.6)
Abbreviation: MD STARnet, Muscular Dystrophy Surveillance, Tracking, and Research Network
Note: Because of rounding, percentages may not total 100.
a
Findings are based on surveillance data.
b
The n does not add up to the overall N for participants and nonparticipants because of missing values.
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Table 2
Types of CAM Used by MD STARnet Families
CAM Type
Yesa
n (%)
Provider Recommendedb
n (%)
Biologically based
 Herbs, mouth 37 (23.1) 11 (29.7)
 Herbs, skin 11 (6.9) 1 (9.1)
 Special diet 54 (33.8) 37 (68.5)
 Megavitamins 11 (6.9) 5 (45.5)
 Glycoproteins 6 (3.8) 1 (16.7)
Manipulative and body-based
 Massage 43 (26.9) 17 (39.5)
 Chiropractic manipulation 29 (18.1) 4 (13.8)
 Osteopathic manipulation 4 (2.5) 1 (25.0)
Mind-body medicine
 Aquatherapy 82 (51.3) 56 (68.3)
 Hippotherapy 24 (15.0) 9 (37.5)
 Self-hypnosis 2 (1.3) 0 (0.0)
 Prayer/blessings 61 (38.1) 1 (1.6)
 Companion animals 11 (6.9) 1 (9.1)
Whole medical systems
 Acupuncture 6 (3.8) 1 (16.7)
 Homeopathy 13 (8.1) 4 (30.8)
Other 18 (11.3) 0 (0.0)
Abbreviations: CAM, complementary and alternative medicine; MD STARnet, Muscular Dystrophy Surveillance, Tracking, and Research Network.
a
Denominator used to calculate the percentages is the number of families reporting any use of CAM (N = 160).
b
Denominator used to calculate the percentages is the number of users for each specific CAM therapy.
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Table 3
Use of CAM Therapies From Specific Domains
CAM Domains
Yesa (N = 160)
n (%)
One domain
 Biologically based only 23 (14.4)
 Manipulative body-based only 9 (5.6)
 Mind-body only 38 (23.8)
Two domains
 Biologically based and manipulative body-based 3 (1.9)
 Biologically based and mind-body 37 (23.1)
 Biologically based and whole medical system 1 (0.6)
 Manipulative body-based and mind-body 17 (10.6)
Three domains
 Biologically based, manipulative body-based, and mind-body 16 (10.0)
 Biologically based, mind-body, and whole medical systems 3 (1.9)
 Biologically based, manipulative body-based, and whole medical systems 1 (0.6)
All four domains
 Biologically based, manipulative body-based, mind-body, and whole medical systems 12 (7.5)
Abbreviation: CAM, complementary and alternative medicine.
a
Denominator used to calculate the percentages is the number of families reporting any use of CAM (N = 160).
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